Eugene Ryan, MD
Internal Medicine · Chattanooga, TNNPI 1609865088
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Novo Nordisk at 57.2% of the total. Reporting peaked in 2020 at $9,936 and has fallen 98.8% since, to $116 in 2025. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $113.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$15K
- Johnson & Johnson$2K
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim International GmbH$1K
- Chiesi USA, Inc.$772
- plus $2K from 35 others
Across 209 payments — averaging $2937.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$255K
- Kowa Research Institute, Inc.$111K
- AstraZeneca$83K
- Eli Lilly$45K
- Amgen$32K
- Sanofi US Services Inc.$31K
- plus $57K from 6 others
What the payments were for
- Consulting fees$7,38828%
- Speaking & faculty fees$10,36340%
- Travel & lodging$3,00112%
- Food & beverage$5,28020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $14,894 |
| Johnson & Johnson | 8 | $2,222 |
| GSK | 2 | $2,203 |
| AstraZeneca | 28 | $2,149 |
| Boehringer Ingelheim International GmbH | 12 | $1,459 |
| Chiesi USA, Inc. | 2 | $772 |
| Amgen | 22 | $398 |
| Boehringer Ingelheim | 5 | $220 |
| Sanofi-aventis U.S. LLC | 7 | $191 |
| Pfizer | 12 | $182 |
| AbbVie | 10 | $162 |
| Esperion Therapeutics, Inc. | 4 | $150 |
| Bayer | 4 | $147 |
| Abbott | 7 | $139 |
| Lifescan, Inc. | 1 | $109 |
| Mallinckrodt Enterprises LLC | 3 | $54 |
| Merck | 4 | $45 |
| Amarin Pharma, Inc. | 3 | $43 |
| Novartis | 3 | $41 |
| Astellas Pharma US Inc | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Boston Scientific | 2 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Dexcom, Inc. | 2 | $28 |
| Intuitive Surgical | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Insulet Corporation | 1 | $24 |
| Nevro Corp. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Mannkind Corporation | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,032 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $106,529 |
| OzempicSemaglutide | 57 | $85,917 |
| FarxigaDapagliflozin Propanediol | 55 | $49,150 |
| XareltoRivaroxaban | 29 | $33,736 |
| JardianceEmpagliflozin | 24 | $26,507 |
| Glucagon Emergency KitGlucagon | 16 | $19,653 |
| JanuviaSitagliptin Phosphate | 16 | $18,980 |
| TrulicityDulaglutide | 16 | $17,885 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $17,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,403 |
| Repatha SureclickEvolocumab | 12 | $12,817 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $6,551 |
| Atorvastatin Calcium | 404 | $5,020 |
| Omeprazole | 294 | $4,069 |
| DilantinPhenytoin Sodium Extended | 13 | $3,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Dilantin | $182 | $110,386108 claims |
| Novo NordiskOzempic | $14,894 | $85,91757 claims |
| AstraZenecaFarxiga | $2,149 | $49,15055 claims |
| Johnson & JohnsonXarelto | $2,222 | $33,73629 claims |
| Boehringer IngelheimJardiance | $220 | $26,50724 claims |
| MerckJanuvia | $45 | $18,98016 claims |
| Lilly USA, LLCTrulicity | $28 | $17,88516 claims |
| GSKTrelegy Ellipta | $2,203 | $15,40315 claims |
| AbbVieSynthroid | $162 | $1,54130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Chattanooga
- Maighan SeagroveChattanooga$78K
- Carlton VollbergChattanooga$30K
- Jeremy HogstromChattanooga$30K
- Jermaine HogstromChattanooga$29K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Dennis DeruelleKnoxville$263K
- Devin ShermanFranklin$191K
- Lewis HagoodKnoxville$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.